drugset
drugset / Trial / NCT07352423

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

NCT07352423 ↗

Phase 1 Recruiting 48 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.

Timeline

Start
2026-03-26
Primary completion
2026-12-23
Completion
2026-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ALXN2230 Unknown — Subcutaneous

Indications

No indication recorded.